ArticleCancer medicine2026
Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD-1 Inhibitors in Advanced Hepatocellular Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsThis study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti-programmed cell death protein 1 (anti-PD-1) therapy in advanced hepatocellular carcinoma (HCC).
methodsIn this retrospective cohort study, patients with advanced HCC received FOLFOX-HAIC or HAIC combined with anti-PD-1 (camrelizumab). Progression-free survival (PFS) was evaluated as the time-to-event outcome, while therapeutic efficacy was assessed using tumor response rates. The Kaplan-Meier method and log-rank test were used to compare PFS. In the MRI-PDFF subset, receiver operating characteristic (ROC) analysis was used to determine the optimal PDFF cutoff for predicting nonresponse (SD or PD).
resultsBetween September 2020 and August 2025, 103 patients were included, of whom 47 received HAIC monotherapy and 56 received HAIC combined with anti-PD-1 therapy. The HAIC-PD1 group demonstrated significantly longer PFS compared with the HAIC group (HR 0.423; 95% CI 0.218-0.818; p = 0.0085), and a higher objective response rate (ORR: 46.4% vs. 21.3%; p = 0.012). In the MRI-PDFF subset, baseline intratumoral PDFF was associated with treatment response. ROC analysis identified an optimal PDFF cutoff of 2.64% for predicting nonresponse (AUC 0.784; 95% CI 0.664-0.903). Patients with PDFF < 2.64% achieved a higher ORR and longer PFS compared with those with PDFF ≥ 2.64%. Longitudinal analyses showed treatment-dependent changes in PDFF after HAIC-PD1 therapy; however, ΔPDFF did not differ significantly between responders and nonresponders.
conclusionHAIC combined with anti-PD-1 therapy demonstrated superior efficacy compared with HAIC monotherapy in advanced HCC. Baseline intratumoral PDFF may serve as a promising imaging biomarker associated with treatment response in patients receiving HAIC-PD1 therapy. Its potential prognostic relevance for time-to-event outcomes requires further validation in prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.